Position in AKBA
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$92,280
+$50,813 QoQ
Shares Held
80,948
+171.3% QoQ
Ownership
0.029%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#70
of 170 holders
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 30%
Shared 0%
None 70%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Focus Partners Wealth holds $57,760,663 across 23 Drug Manufacturers - Specialty & Generic names. AKBA ranks #20 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
77,994 | $13,145,108 | |
| 2 | ZTS |
Zoetis Inc.
|
180,366 | $12,961,100 | |
| 3 | TAK |
Takeda Pharmaceutical Co Ltd
|
679,950 | $10,899,598 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
67,843 | $7,526,502 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
6,078 | $3,293,242 | |
| 6 | ALKS |
Alkermes plc.
|
41,596 | $2,179,630 | |
| 7 | HLN |
Haleon plc
|
221,287 | $2,064,607 | |
| 8 | TEVA |
Teva Pharmaceutical Industries Ltd
|
35,560 | $1,204,772 |
All Filings in AKBA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $92,280 | 80,948 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $41,467 | 29,833 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $75,187 | 46,700 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $83,513 | 30,591 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $48,291 | 13,267 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $21,870 | 11,391 | Shares | Sole | 2025-05-20 | |
| 2024-12-31 | $20,694 | 10,892 | Shares | Sole | 2025-05-29 | |
| 2024-06-30 | $14 | 10,575 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $13 | 10,538 | Shares | Sole | 2024-05-16 | |
| No filing history on record for this holder in this stock. | ||||||